key: cord-0840570-xqpdw5me
authors: Yoon, Jong Pil; Jung, Young Soo; Kim, Dong Hyun
title: Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: Two cases, infectious and inflammatory
date: 2022-05-10
journal: JSES Rev Rep Tech
DOI: 10.1016/j.xrrt.2022.04.005
sha: 03cc0e2b9b8278ad9934cabc7da182baa33ec967
doc_id: 840570
cord_uid: xqpdw5me

nan

Post-AZD1222 local myofascitis of deltoid muscle 2 On April 29, 2021, AZD1222 was administered to a 41-year-old female patient on the direct 24 lateral portion left deltoid muscle (in the center of the deltoid muscle, midway between the 25 acromion and the deltoid tuberosity). About 12 hours after vaccination, a mild fever of 37~38 26 ºC with localized heat and tenderness, erythema, and edema developed around the inoculation 27 site. Pain of Visual Analogue Scale (VAS) 6 was also accompanied by active movement of the 28 left shoulder. Although She took only 500 mg of acetaminophen three times a day and observed 29 these symptoms without any other special treatments, she showed no improvement even after 30 3 days.

Hence, she visited our hospital as an outpatient; her body temperature was 36.9°C, and there 32 was erythema of about 7cm in diameter around the vaccination site, accompanied by swelling 33 and heat. Tenderness was most severe at the injection site. Resting pain was VAS 4~5, and it 34 was most severe with VAS 6 in abduction of the shoulder joint. She did not have any specific was reduced to about 5cm in diameter, and the erythema, warmth, and edema decreased, and 48 the tenderness was similar. Resting pain was VAS 4, and pain during active motion was VAS 49 5. The white blood count (WBC), ESR, and CRP level were still within the normal range. In 50 collaboration with an infectious disease physician, we changed the antibiotic to a third-51 generation cephalosporin (2 g/day in 2 divided doses) to be administered intravenously for 3 52 days; however, there was no improvement in symptoms. Hence, piperacillin sodium 4 g/ 53 tazobactam 0.5 g was administered 3 times a day every 8 h. Two days later, most symptoms within the normal range, but active abduction was limited to 90~100° due to pain. Also, she 67 had mild tenderness and swelling around the vaccination site, but there was no heat or erythema.

She continued to take only acetaminophen for a week without any other treatment. However, 69 after 10 days, her pain did not improve, and she visited our institution's outpatient clinic. She 

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-163 19

Diagnosis 201 and Management of Vaccine-Related Thrombosis following AstraZeneca

Vaccination: Guidance Statement from the GTH

AstraZeneca COVID-19 vaccine: side-effect or 206 coincidence?

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-209 boost regimen in young and old adults (COV002): a single-blind, randomised, 210 controlled, phase 2/3 trial

Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is 213 ideal for resource-constrained low-and middle-income countries

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

Unilaterally dominant eosinophilic 219 fasciitis after influenza vaccination

Necrotizing fasciitis following BCG vaccination

Side effect worry grows for AstraZeneca vaccine

Safety 226 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an 227 interim analysis of four randomised controlled trials in Brazil, South Africa, and the 228 UK